Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 27179402

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2016 Jun
First author
Gianni L

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Jun;17(6):693-694. doi: 10.1016/S1470-2045(16)30038-9.
    note
    Source null
    related pmid
    27179401
    relationship
    Comment in

Authors and identifiers

  1. name
    Gianni L
    type
    Author
  2. name
    Pienkowski T
    type
    Author
  3. name
    Im YH
    type
    Author
  4. name
    Tseng LM
    type
    Author
  5. name
    Liu MC
    type
    Author
  6. name
    Lluch A
    type
    Author
  7. name
    Starosławska E
    type
    Author
  8. name
    de la Haba-Rodriguez J
    type
    Author
  9. name
    Im SA
    type
    Author
  10. name
    Pedrini JL
    type
    Author
  11. name
    Poirier B
    type
    Author
  12. name
    Morandi P
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Gianni L
    type
    Author
  2. name
    Pienkowski T
    type
    Author
  3. name
    Im YH
    type
    Author
  4. name
    Tseng LM
    type
    Author
  5. name
    Liu MC
    type
    Author
  6. name
    Lluch A
    type
    Author
  7. name
    Starosławska E
    type
    Author
  8. name
    de la Haba-Rodriguez J
    type
    Author
  9. name
    Im SA
    type
    Author
  10. name
    Pedrini JL
    type
    Author
  11. name
    Poirier B
    type
    Author
  12. name
    Morandi P
    type
    Author
bibliography ids
  1. nci-bib-18fde5f4cc6aab083b70db1b
book metadata
content sha256
0fca0c10d6cd3b0c0a12510b54e44910801519dd13f7e45d726ca7a1202e6477
document type
citation
dois
  1. 10.1016/S1470-2045(16)00163-7
electronic publication date
display
2016 May 11
precision
day
year
2016
evidence scope
bibliographic_metadata_only
id
pubmed:27179402
immutable id
pubmed:27179402@0fca0c10d6cd3b0c0a12510b54e44910801519dd13f7e45d726ca7a1202e6477
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
6
name
The Lancet. Oncology
nlm unique id
100957246
pages
791-800
volume
17
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Jun;17(6):693-694. doi: 10.1016/S1470-2045(16)30038-9.
    note
    Source null
    related pmid
    27179401
    relationship
    Comment in
outcomes validated
false
pmid
27179402
provenance
batch id
fe5a46c92522c34737e8
provider
NCBI PubMed ESummary
record sha256
3a33193585306a06788e4bd1c69c108992912e3902f9fd18c137f906a4cea4d9
response sha256
2c7bacd02d2ece3813daf1a0f92260c22884bd9268942fcca2088ab229bfb4d1
retrieved at
2026-09-09T23:47:17.939307+00:00
publication date
display
2016 Jun
precision
month
year
2016
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/27179402/
title
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.

Preserved source evidence · Not medical advice